Tigecycline

Tigecycline

Catalog Number:
M001341742TOK
Mfr. No.:
TOK-T022
Price:
$220
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Tigecycline is a broad spectrum glycylcycline antibiotic useful for multi-drug resistant organisms and approved by the FDA in June 2005. Tigecycline is a semisynthetic derivative of tetracycline, that is structurally similar to minocycline; however, it contains a large glycylamido group at the D-9 position. This substitution is thought to be the reason behind its broad-spectrum activity.
          Tigecycline is a protein synthesis inhibitor, that show bacteriostatic activity against both Gram-positive and Gram-negative bacteria. It was designed be less affected by the two major tetracycline-resistance mechanisms, ribosomal protection and efflux. Additionally, Tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target-site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerases). However, some ESBL-producing isolates may confer resistance to Tigecycline via other resistance mechanisms. Tigecycline resistance in some bacteria (e.g. Acinetobacter calcoaceticus-Acinetobacter baumannii complex) is associated with multi-drug resistant (MDR) efflux pumps.
          Tigecycline has recently shown anti-tumor properties and is being evaluated for Tigecycline’s inhibitory effects on several activating signaling pathways and abnormal mitochondrial function in cancer cells.
          Tigecycline is soluble in water (0.45 mg/mL) and DMSO (>3 mg/mL).

          This product is considered a dangerous good. Quantities above 1 g may be subject to additional shipping fees. Please contact us for specific questions.

          Please contact us at for specific academic pricing.

          Background

          Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. In general, Tigecycline is considered bacteriostatic; however, Tigecycline has demonstrated bactericidal activity against isolates of S. pneumoniae and L. pneumophila.

      • Properties
        • CAS Number
          220620-09-7
          Molecular Formula
          C29H39N5O8
          Molecular Weight
          585.65
          Appearance
          Orange to orange-red colored crystalline powder
          Other Properties
          Source: Semi-synthetic
          Water Content (Karl Fischer): Not more than 2.0%
          Assay: (As Is): 98.0-102.0%
          Residue On Ignition: Not more than 0.1%
          Heavy Metals: Not more than 20 ppm
          Optical Rotation: -205° - -230°
          Identification: IR, HPLC - Passes test
          Storage
          -20°C

          * For research use only

      • Applications
        • Application Description
          Spectrum: Tigecycline has broad-spectrum activity against most Gram-positive and Gram-negative bacteria including multi-drug resistant organisms such as MRSA. Tigecycline has also been found to be effective against carbapenem resistant Enterobacteriaceae or CRE. CRE is a "superbug" which possesses NDM-1 or KPC genes which encode New Delhi Metallo-beta-lactamase or Klebsiella pneumoniae cabapenemase respectively; two enzymes which render nearly all beta-lactam antibiotics useless.

          Microbiology Applications: Tigecycline is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram positive and Gram negative microbial isolates. Tigecycline has also shown high potency against high-resistant superbug strains. Medical microbiologists use AST results to recommend antibiotic treatment options for infected patients. Representative MIC values include: Staphylococcus aureus (methicillin resistant) 0.03 µg/mL - 2 µg/mL Streptococcus pneumoniae 0.015 µg/mL – 2 µg/mL
          Cancer Applications: An increasing number of studies have emphasized the anti-tumor effects of Tigecycline. The inhibitory effects of Tigecycline on cancer depend on activating several signaling pathways and abnormal mitochondrial function in cancer cells. Tigecycline has shown anti-tumor activity against different cancer types, including acute myeloid leukemia (AML), glioma, non-small cell lung cancer (NSCLC), among others.

    Note: If you don't receive our verification email, do the following:

  • Copyright © Amerigo Scientific. All rights reserved.